Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New anti-inflammatory strategy for cancer therapy identified

21.09.2004


A new strategy for cancer therapy, which converts the tumor-promoting effect of the immune system’s inflammatory response into a cancer-killing outcome, is suggested in research findings by investigators at the University of California, San Diego (UCSD) School of Medicine.



The findings provide new insight into the immune system’s response to inflammation, the connection between inflammation and malignancy, and how the delicate balance between cancer promotion and inhibition can be manipulated in the patient’s favor, according to the study’s senior author, Michael Karin, Ph.D., UCSD professor of pharmacology, American Cancer Society Research Professor, and a member of the Rebecca and John Moores UCSD Cancer Center.

The studies in mice with colon or breast cancer showed that cancer metastasis, the growth of malignant tumors beyond the original site, was halted with inhibition of either one of two naturally occurring substances, a pro-inflammatory protein called nuclear factor-kappa B (NF-kB) or an inflammatory mediator called tumor necrosis factor alpha (TNFá). The result, published in the September 20, 2004 issue of the journal Cancer Cell, was increased effectiveness of a cancer-killing protein called TNF-related apoptosis-inducing ligand (TRAIL), leading to a decrease in cancer cells and increase in the life span of tumor-bearing mice.


The study’s first author, Jun-Li Luo, M.D., Ph.D., a member of the Karin team in the UCSD Laboratory of Gene Regulation and Signal Transduction, explained that normally, inflammation associated with malignancy activates NF-kB, TNFá and TRAIL, all at the same time. However, NF-kB has the upper hand, and with TNFá, stimulates tumor growth faster than TRAIL can inhibit it. "Our results suggest that is it possible to use NF-kB or TNFá inhibitors to prevent inflammation-induced tumor growth, thus destroying their advantage, and allowing TRAIL to tip the balance in its favor," Luo said.

The study builds upon previous work in the Karin lab recently featured as the cover article in the August 6, 2004 issue of the journal Cell*. In that study, the researchers provided the first evidence of the molecular link between inflammation and cancer. They determined that an enzyme called I-kappa-B kinase beta (IKKâ) is required for the activation of NF-kB, which acts as a master switch to turn on inflammation in response to bacterial or viral infections. In turn, NF-kB sets off a chain of reactions that lead to cancer.

Mice used in the new study were given colon or breast tumor cells which metastasized to the lung. Some of these cancer cells served as "controls," while other cells were given a protein that specifically inhibited activation of NF-kB, only in cancer cells. The different cells were injected into mice and all were able to establish metastatic growth in the lung, regardless of their ability or inability to activate NF-kB. After a week, all mice were injected with bacterial lipopolysaccchide (LPS), which induced inflammation. A post-mortum inspection of the mice showed that following inflammation, the control cells formed more numerous and larger tumor nodules, while the tumors formed by cells in which NF-kB was inhibited, had shrunk or partially disappeared after the LPS injection. As a result, mice injected with cancer cells lacking NF-kB activity exhibited much better survival than mice inoculated with control cells.

In further tests to determine how NF-kB activation mediates inflammation-induced tumor growth, the team studied mouse lung tissue as well as tumor nodules for expression of specific proteins known to modulate the body’s normal cell-killing process. Death-inhibiting proteins were abundant in tumors formed by cancer cells with normal NF-kB, but were absent in the tumors formed by cancer cells where NF-kB was inhibited.

While NF-kB is known to convert inflammatory stimuli into tumor growth signals, it is also known to activate TNFá, a major proinflammatory protein initially thought to play a role in the death of cancer cells. Investigators first reasoned that TNFá might be responsible for the death of cancer cells in which NF-kB was inhibited, seen in this study, since previous experiments have shown that high doses of TNFá can kill tumor cells when NF-kB activity is inhibited.

However, further experiments proved otherwise. When inflammation-inducing LPS was administered to tumor-bearing mice with normal NF-kB, the result was a rapid and robust induction of circulating TNFá and eventual acceleration of cancer growth. However, administration of an anti-TNFá antibody five minutes after LPS challenge neutralized most of the circulating TNFá, inhibited NF-kB activation in cancer cells, and prevented the inflammation-induced acceleration of tumor growth.

Rather than TNFá, the team found that TRAIL, a member of the TNF superfamily and a relative of TNFá, was the specific protein responsible for the tumor death response. While both NF-kB and TRAIL are activated in response to inflammation, NF-kB takes control, inhibits cell death and promotes cancer growth. When NF-kB or TNFá were inhibited, however, TRAIL was able to strongly assert its ability to reduce tumor growth by killing cancer cells. The role of TRAIL was further illustrated in additional experiments where a neutralizing anti-TRAIL antibody was injected into the mice following the LPS challenge. The result was tumor growth.

In their summary, the researchers said that since TNFá does not make a major contribution to tumor killing and instead may promote tumor growth, it may be advisable to develop drugs which reduce inflammation-associated toxicities, block inflammation-induced tumor growth and clear the way for TRAIL to initiate tumor killing. The latter approach can be accomplished by the use of NF-kB inhibitors, together with anti-TNFá drugs, the researchers contend. These drugs should be used in combination with TRAIL or TRAIL-inducing cytokines, such as beta interferon.

Sue Pondrom | EurekAlert!
Further information:
http://www.ucsd.edu

More articles from Life Sciences:

nachricht New risk factors for anxiety disorders
24.02.2017 | Julius-Maximilians-Universität Würzburg

nachricht Stingless bees have their nests protected by soldiers
24.02.2017 | Johannes Gutenberg-Universität Mainz

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Breakthrough with a chain of gold atoms

In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport

In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport

Im Focus: DNA repair: a new letter in the cell alphabet

Results reveal how discoveries may be hidden in scientific “blind spots”

Cells need to repair damaged DNA in our genes to prevent the development of cancer and other diseases. Our cells therefore activate and send “repair-proteins”...

Im Focus: Dresdner scientists print tomorrow’s world

The Fraunhofer IWS Dresden and Technische Universität Dresden inaugurated their jointly operated Center for Additive Manufacturing Dresden (AMCD) with a festive ceremony on February 7, 2017. Scientists from various disciplines perform research on materials, additive manufacturing processes and innovative technologies, which build up components in a layer by layer process. This technology opens up new horizons for component design and combinations of functions. For example during fabrication, electrical conductors and sensors are already able to be additively manufactured into components. They provide information about stress conditions of a product during operation.

The 3D-printing technology, or additive manufacturing as it is often called, has long made the step out of scientific research laboratories into industrial...

Im Focus: Mimicking nature's cellular architectures via 3-D printing

Research offers new level of control over the structure of 3-D printed materials

Nature does amazing things with limited design materials. Grass, for example, can support its own weight, resist strong wind loads, and recover after being...

Im Focus: Three Magnetic States for Each Hole

Nanometer-scale magnetic perforated grids could create new possibilities for computing. Together with international colleagues, scientists from the Helmholtz Zentrum Dresden-Rossendorf (HZDR) have shown how a cobalt grid can be reliably programmed at room temperature. In addition they discovered that for every hole ("antidot") three magnetic states can be configured. The results have been published in the journal "Scientific Reports".

Physicist Dr. Rantej Bali from the HZDR, together with scientists from Singapore and Australia, designed a special grid structure in a thin layer of cobalt in...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Booth and panel discussion – The Lindau Nobel Laureate Meetings at the AAAS 2017 Annual Meeting

13.02.2017 | Event News

Complex Loading versus Hidden Reserves

10.02.2017 | Event News

International Conference on Crystal Growth in Freiburg

09.02.2017 | Event News

 
Latest News

Stingless bees have their nests protected by soldiers

24.02.2017 | Life Sciences

New risk factors for anxiety disorders

24.02.2017 | Life Sciences

MWC 2017: 5G Capital Berlin

24.02.2017 | Trade Fair News

VideoLinks
B2B-VideoLinks
More VideoLinks >>>